SAMHD1 Phosphorylation Coordinates the Anti-HIV-1 Response by Diverse Interferons and Tyrosine Kinase Inhibition

• Published in: mBio 2018-05, Vol.9 (3)
• Main Authors: Szaniawski, Matthew A, Spivak, Adam M, Cox, James E, Catrow, Jonathan L, Hanley, Timothy, Williams, Elizabeth S C P, Tremblay, Michel J, Bosque, Alberto, Planelles, Vicente
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Amino Acid Motifs; Antiviral Agents - pharmacology; CDK1; dasatinib; Female; HIV Infections - genetics; HIV Infections - metabolism; HIV Infections - virology; HIV-1 - drug effects; HIV-1 - genetics; HIV-1 - physiology; human immunodeficiency virus; Humans; interferon; Interferons - genetics; Interferons - immunology; macrophages; Macrophages - immunology; Male; Phosphorylation; Protein Kinase Inhibitors - pharmacology; Protein-Tyrosine Kinases - antagonists & inhibitors; Protein-Tyrosine Kinases - genetics; Protein-Tyrosine Kinases - metabolism; SAM Domain and HD Domain-Containing Protein 1 - chemistry; SAM Domain and HD Domain-Containing Protein 1 - genetics; SAM Domain and HD Domain-Containing Protein 1 - metabolism; Young Adult
• ISSN: 2161-2129; 2150-7511
• DOI: 10.1128/mBio.00819-18

Macrophages are susceptible to human immunodeficiency virus type 1 (HIV-1) infection despite abundant expression of antiviral proteins. Perhaps the most important antiviral protein is the restriction factor sterile alpha motif domain and histidine/aspartic acid domain-containing protein 1 (SAMHD1). We investigated the role of SAMHD1 and its phospho-dependent regulation in the context of HIV-1 infection in primary human monocyte-derived macrophages and the ability of various interferons (IFNs) and pharmacologic agents to modulate SAMHD1. Here we show that stimulation by type I, type II, and to a lesser degree, type III interferons share activation of SAMHD1 via dephosphorylation at threonine-592 as a consequence of signaling. Cyclin-dependent kinase 1 (CDK1), a known effector kinase for SAMHD1, was downregulated at the protein level by all IFN types tested. Pharmacologic inhibition or small interfering RNA (siRNA)-mediated knockdown of CDK1 phenocopied the effects of IFN on SAMHD1. A panel of FDA-approved tyrosine kinase inhibitors potently induced activation of SAMHD1 and subsequent HIV-1 inhibition. The viral restriction imposed via IFNs or dasatinib could be overcome through depletion of SAMHD1, indicating that their effects are exerted primarily through this pathway. Our results demonstrate that SAMHD1 activation, but not transcriptional upregulation or protein induction, is the predominant mechanism of HIV-1 restriction induced by type I, type II, and type III IFN signaling in macrophages. Furthermore, SAMHD1 activation presents a pharmacologically actionable target through which HIV-1 infection can be subverted. Our experimental results demonstrate that SAMHD1 dephosphorylation at threonine-592 represents a central mechanism of HIV-1 restriction that is common to the three known families of IFNs. While IFN types I and II were potent inhibitors of HIV-1, type III IFN showed modest to undetectable activity. Regulation of SAMHD1 by IFNs involved changes in phosphorylation status but not in protein levels. Phosphorylation of SAMHD1 in macrophages occurred at least in part via CDK1. Tyrosine kinase inhibitors similarly induced SAMHD1 dephosphorylation, which protects macrophages from HIV-1 in a SAMHD1-dependent manner. SAMHD1 is a critical restriction factor regulating HIV-1 infection of macrophages.